Anti-IL-33 and anti-ST2 antibodies are examined in the therapy of various inflammatory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, etc., in the second phase of clinical studies; however, their role in cancer therapy has not been fully investigated [10]. This evidence concerns the gene IL33 and chronic obstructive pulmonary disease.